Leo Pharma is establishing a Chinese affiliate to market Leo Pharma's portfolio of drugs for the treatment of the chronic skin disease psoriasis and other dermatological products.

Leo Pharma's leading psoriasis brand, Daivobet, has just been approved by the Chinese authorities and can now be marketed in China, according to the company.

Leo Pharma's new company in China underpins Leo Pharma's long-term global strategy of providing patients that suffer from psoriasis with the best topical treatments possible.

The setting-up of Leo Pharma China is regarded as a long term investment for the Leo Group, says Gitte Aabo, CEO and president of Leo Pharma: "The project in China can lead to significant investments for Leo Pharma, but the earnings potential in one of the fastest growing markets for pharmaceuticals can also be huge in the long term."